By enabling early detection, optimized clinical workflows, and reduced antibiotic overuse, VIOSync is poised to transform sepsis care
We are excited to share that Aisthesis Medical has been selected for the MARRS Programme by CPI UK, an initiative designed to accelerate regulatory pathways for cutting-edge MedTech innovations.
This support will be instrumental in fast-tracking the regulatory approval and market adoption of VIOSync, our AI-powered sepsis prediction and management platform. By enabling early detection, optimized clinical workflows, and reduced antibiotic overuse, VIOSync is poised to transform sepsis care.
What this means for Aisthesis Medical
Regulatory acceleration for CE MDR & FDA 510(k) compliance
Expert guidance to navigate market access barriers
Enhanced scalability for hospital-wide integration
With this support, we are one step closer to bringing VIOSync to hospitals globally, ensuring better patient outcomes and improved sepsis management.
Stay tuned as we share our journey through the MARRS Programme!
About Aisthesis Medical
Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven sepsis care platform that goes beyond early prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.